ClinicalTrials.gg
CompletedNCT03100045ART-AINUpdated Nov 3, 2021

Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)

A Phase 1 interventional study of Artesunate Suppositories in HPV-Related Anal Intraepithelial Neoplasia, AIN2/3 and Artesunate, sponsored by Johns Hopkins University. Completed at 2 sites in United States. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2021-11-03.

Sponsored by Johns Hopkins University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 151 studies in Precancerous Conditions with a site in United States — 6 open to participants now, 12 under way, 2 of them phase 3. Precancerous Conditions · United States.

Enrollment
87th of 105
18 · median 58
Started
2017
with 2 others
Phase 1
26 of 151
none open now
Registered
138th of 151
by date

Among the 151 studies in Precancerous Conditions with a site in United States, this one is the 87th largest by enrollment of the 105 interventional ones that give a count, is one of 3 that started in 2017, is one of 26 in phase 1, and was the 138th registered.

Precancerous Conditions

217 studies on the registry are indexed under Precancerous Conditions; 16 are open to participants now.

Browse Precancerous Conditions studies →

Open to participants now

6 of the 151 studies in Precancerous Conditions with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 12 Precancerous Conditions studies recruiting now, 6 (50%) set no upper age limit and 1 (8%) stops at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 151 studies in Precancerous Conditions with a site in United States, or all of them as a file.
02

Study summary

This open label study investigates a novel non-surgical approach to the treatment of HPV-associated anal intraepithelial neoplasia, using Artesunate suppositories.

Read the detailed description

Patients diagnosed with AIN 2/3 will be enrolled sequentially in treatment cohorts receiving different doses of Artesunate suppositories administered trans-anally. Doses of escalation will be 200 mg, 400 mg, and 600 mg. Treatment cohorts will consist of 2 or 3 cycles at each dose level. Suppositories will be administered daily for 5 days. Five days constitutes 1 cycle. Up to 3 cycles will be administered at Weeks 0, 2, and 4.

03

Conditions studied

  • HPV-Related Anal Intraepithelial Neoplasia
  • AIN2/3
  • Artesunate
  • Alternative Treatment
  • Anal Dysplasia
  • Precancerous Conditions
  • Human Papilloma Virus

Keywords

  • HPV
  • suppository
  • Artesunate
  • artemisinin
  • anal dysplasia
  • treatment
  • alternative treatment
  • anal precancer
  • Johns Hopkins
  • Sandy Fang
  • Frantz Viral Therapeutics
  • Wisconsin
  • Evie Carchman
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • -confirmed high-grade anal dysplasia (AIN 2, AIN 3, HSIL) by high resolution anoscopy (HRA)
  • Female of : negative urine pregnancy test
  • Able to provide
  • Patients who have the ability to collaborate with planned follow-up (transportation, compliance history, etc.).
  • Weight ≥50 kg.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of low-grade anal dysplasia (AIN 1, LSIL) by high resolution anoscopy
  • Known anal, vulvar, cervical, or penile cancer
  • \< 200 at the time of consideration for entry into this study
  • Unable to provide
  • Currently receiving systemic chemotherapy or radiation therapy for another cancer.
  • Patients who are on medical treatment with systemic or (e.g., active disease)
  • Extensive anal condyloma precludes the ability for the clinician to visualize HSIL during HRA
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    ART 200 mg, 2 cycles

    Two five-day cycles of Artesunate suppositories, 200 mg/day

    Drug: Artesunate Suppositories

  • Experimental
    ART 200 mg, 3 cycles

    Three five-day cycles of Artesunate suppositories, 200 mg/day

    Drug: Artesunate Suppositories

  • Experimental
    ART 400 mg, 2 cycles

    Two five-day cycles of Artesunate suppositories, 400 mg/day

    Drug: Artesunate Suppositories

  • Experimental
    ART 400 mg, 3 cycles

    Three five-day cycles of Artesunate suppositories, 400 mg/day

    Drug: Artesunate Suppositories

  • Experimental
    ART 600 mg, 2 cycles

    Two five-day cycles of Artesunate suppositories, 600 mg/day

    Drug: Artesunate Suppositories

  • Experimental
    ART 600 mg, 3 cycles

    Three five-day cycles of Artesunate suppositories, 600 mg/day

    Drug: Artesunate Suppositories

Interventions

  • DrugArtemisininStudies of ArtemisininArtemisinin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia

    Also known as: Artemisinin

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (Safety and tolerability) of Artesunate suppositories for the treatment of anal intraepithelial neoplasia (AIN2/3)

    Number of patients with serious adverse events or dose limiting toxicities related to the study medication, according to CTCAE4.0

    Time frame: 6 weeks from the date of the first dosing

Secondary outcomes

  1. Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less

    Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy

    Time frame: 16 weeks

  2. Number of patients with histologic regression of anal intraepithelial neoplasia (AIN2/3) to AIN1 or less

    Number of patients with no AIN2/3 as assessed by high resolution anoscopy and biopsy

    Time frame: 28 weeks

  3. Number of patients with viral clearance of human papillomavirus (HPV) virus measured by HPV genotyping

    Number of patients with HPV genotypes present at study entry which become undetectable during the study window

    Time frame: 40 weeks

07

Study locations

2 sites
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in Oct 2021, 53 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2017
First posted
Apr 4, 2017
StartActual
Apr 20, 2017
Primary completionActual
Oct 6, 2021
CompletionActual
Oct 6, 2021
Last update
Nov 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03100045
Collaborators
Frantz Viral Therapeutics, LLC, University of Wisconsin, Madison
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Apr 20, 2017
Primary completion
Oct 6, 2021
Completion
Oct 6, 2021
Last update
Nov 3, 2021

Study contacts

Sandy H Fang, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Artemisinin

Start the discussion